This case shares similarities with early-onset, severe AIHA induced by pembrolizumab, as reported by Adeoye et al. (16) and Back et al. (17), supporting the possibility that such hyperacute hematologic toxicity may represent a class effect of PD-1 inhibitors. This evidence concerns the gene PDCD1 and autoimmune hemolytic anemia.